Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value
Purpose Identification of the mismatch repair (MMR) deficiency in endometrial cancer (EC) may aid in the screening of patients who may benefit from immunotherapy. Our goal was to investigate the relationship between MMR status and 18 F-FDG PET/CT metabolic parameters and clinicopathological features...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2023-12, Vol.37 (12), p.655-664 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 664 |
|---|---|
| container_issue | 12 |
| container_start_page | 655 |
| container_title | Annals of nuclear medicine |
| container_volume | 37 |
| creator | Sun, Xiaolin Yao, Xinchao Zeng, Baozhen Zhu, Linbo Shang, Yuxiang Zhang, Qing He, Li Jiang, Lei |
| description | Purpose
Identification of the mismatch repair (MMR) deficiency in endometrial cancer (EC) may aid in the screening of patients who may benefit from immunotherapy. Our goal was to investigate the relationship between MMR status and
18
F-FDG PET/CT metabolic parameters and clinicopathological features in patients with EC, as well as to explore their prognostic value.
Methods
This retrospective study included 106 EC patients who were classified as MMR deficient (dMMR) or MMR proficient (pMMR) group based on MMR protein expression status evaluated by immunohistochemistry. Clinicopathological characteristics and PET metabolic parameters were compared between the dMMR and pMMR groups, and their relationships with MMR status and prognosis were evaluated.
Results
Of 106 EC patients, 30 patients (28.1%) had dMMR, while 76 (71.7%) had pMMR. Compared with the pMMR group, the dMMR group showed a lower prevalence of overweight (BMI ≥ 25) (17.2% vs. 43.9%,
P
= 0.019) and more lymph vascular space invasion (43.3% vs. 21.1%,
P
= 0.029). Although no relationship between glucometabolism parameters and MMR status was observed in all enrolled patients, higher SUVmax was observed in the endometrioid type of EC with MMR deficiency (
P
= 0.047). Additionally, SUVmax related to MMR status was found in EC patients with advanced FIGO stage (
P
= 0.026) or deep myometrial invasion (
P
= 0.026). Multivariate Cox regression analysis revealed that lymph node metastasis was independently predictive of PFS, while advanced FIGO stage was an independent predictor of OS. No significant association between MMR status and prognosis was found in EC.
Conclusion
Higher SUVmax was associated with MMR deficiency in EC patients with endometrioid type, advanced stage, or deep myometrial invasion, which may be useful for predicting the MMR status and thus aiding in determination of immunotherapy for patients with EC. |
| doi_str_mv | 10.1007/s12149-023-01869-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2868668548</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2890830199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c282t-1dc1ac9e7a5647d36ea379d9009a1a624bdbc8d3a48523833bb838b18038556d3</originalsourceid><addsrcrecordid>eNp9kb1uFDEURi0EEkvgBags0dCY-GfGY5fRkk0iRQrFUlt3bM-uo1l7sT2gPEVeGZONhJQi1b3FOZ_u1YfQZ0a_MUqH88I46zShXBDKlNSEv0GrtnREdkK8RSuqWUcGpob36EMp95Ry1Su-Qo8XpSQboIYUcZrwIZQDVLvH2R8hZOz8FGzw0T7gELGPLh18zQFmbCFan_GfUPeYqQ3ZfL_CPy635-sthuiwnUMMNh2h7tOcdsE2ZfJQl-zLE1D3vuUfc9rFVGqw-DfMi_-I3k0wF__peZ6hn5vL7fqa3N5d3awvbonlilfCnGVgtR-gl93ghPQgBu00pRoYSN6NbrTKCehUz4USYhyVUCNTVKi-l06coa-n3HbAr8WXatrn1s8zRJ-WYriSSkrVd6qhX16g92nJsV3XKE2VoEzrRvETZXMqJfvJHHM4QH4wjJp_HZlTR6Z1ZJ46MrxJ4iSVBsedz_-jX7H-ArDGlSU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2890830199</pqid></control><display><type>article</type><title>Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value</title><source>SpringerLink Journals</source><creator>Sun, Xiaolin ; Yao, Xinchao ; Zeng, Baozhen ; Zhu, Linbo ; Shang, Yuxiang ; Zhang, Qing ; He, Li ; Jiang, Lei</creator><creatorcontrib>Sun, Xiaolin ; Yao, Xinchao ; Zeng, Baozhen ; Zhu, Linbo ; Shang, Yuxiang ; Zhang, Qing ; He, Li ; Jiang, Lei</creatorcontrib><description>Purpose
Identification of the mismatch repair (MMR) deficiency in endometrial cancer (EC) may aid in the screening of patients who may benefit from immunotherapy. Our goal was to investigate the relationship between MMR status and
18
F-FDG PET/CT metabolic parameters and clinicopathological features in patients with EC, as well as to explore their prognostic value.
Methods
This retrospective study included 106 EC patients who were classified as MMR deficient (dMMR) or MMR proficient (pMMR) group based on MMR protein expression status evaluated by immunohistochemistry. Clinicopathological characteristics and PET metabolic parameters were compared between the dMMR and pMMR groups, and their relationships with MMR status and prognosis were evaluated.
Results
Of 106 EC patients, 30 patients (28.1%) had dMMR, while 76 (71.7%) had pMMR. Compared with the pMMR group, the dMMR group showed a lower prevalence of overweight (BMI ≥ 25) (17.2% vs. 43.9%,
P
= 0.019) and more lymph vascular space invasion (43.3% vs. 21.1%,
P
= 0.029). Although no relationship between glucometabolism parameters and MMR status was observed in all enrolled patients, higher SUVmax was observed in the endometrioid type of EC with MMR deficiency (
P
= 0.047). Additionally, SUVmax related to MMR status was found in EC patients with advanced FIGO stage (
P
= 0.026) or deep myometrial invasion (
P
= 0.026). Multivariate Cox regression analysis revealed that lymph node metastasis was independently predictive of PFS, while advanced FIGO stage was an independent predictor of OS. No significant association between MMR status and prognosis was found in EC.
Conclusion
Higher SUVmax was associated with MMR deficiency in EC patients with endometrioid type, advanced stage, or deep myometrial invasion, which may be useful for predicting the MMR status and thus aiding in determination of immunotherapy for patients with EC.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-023-01869-2</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Cancer ; Endometrial cancer ; Endometrium ; Fluorine isotopes ; Imaging ; Immunohistochemistry ; Immunotherapy ; Lymph nodes ; Medicine ; Medicine & Public Health ; Metabolism ; Metastases ; Mismatch repair ; MMR protein ; Myometrium ; Nuclear Medicine ; Original Article ; Parameters ; Positron emission tomography ; Prognosis ; Radiology ; Regression analysis</subject><ispartof>Annals of nuclear medicine, 2023-12, Vol.37 (12), p.655-664</ispartof><rights>The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c282t-1dc1ac9e7a5647d36ea379d9009a1a624bdbc8d3a48523833bb838b18038556d3</citedby><cites>FETCH-LOGICAL-c282t-1dc1ac9e7a5647d36ea379d9009a1a624bdbc8d3a48523833bb838b18038556d3</cites><orcidid>0000-0002-9479-132X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-023-01869-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-023-01869-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Sun, Xiaolin</creatorcontrib><creatorcontrib>Yao, Xinchao</creatorcontrib><creatorcontrib>Zeng, Baozhen</creatorcontrib><creatorcontrib>Zhu, Linbo</creatorcontrib><creatorcontrib>Shang, Yuxiang</creatorcontrib><creatorcontrib>Zhang, Qing</creatorcontrib><creatorcontrib>He, Li</creatorcontrib><creatorcontrib>Jiang, Lei</creatorcontrib><title>Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><description>Purpose
Identification of the mismatch repair (MMR) deficiency in endometrial cancer (EC) may aid in the screening of patients who may benefit from immunotherapy. Our goal was to investigate the relationship between MMR status and
18
F-FDG PET/CT metabolic parameters and clinicopathological features in patients with EC, as well as to explore their prognostic value.
Methods
This retrospective study included 106 EC patients who were classified as MMR deficient (dMMR) or MMR proficient (pMMR) group based on MMR protein expression status evaluated by immunohistochemistry. Clinicopathological characteristics and PET metabolic parameters were compared between the dMMR and pMMR groups, and their relationships with MMR status and prognosis were evaluated.
Results
Of 106 EC patients, 30 patients (28.1%) had dMMR, while 76 (71.7%) had pMMR. Compared with the pMMR group, the dMMR group showed a lower prevalence of overweight (BMI ≥ 25) (17.2% vs. 43.9%,
P
= 0.019) and more lymph vascular space invasion (43.3% vs. 21.1%,
P
= 0.029). Although no relationship between glucometabolism parameters and MMR status was observed in all enrolled patients, higher SUVmax was observed in the endometrioid type of EC with MMR deficiency (
P
= 0.047). Additionally, SUVmax related to MMR status was found in EC patients with advanced FIGO stage (
P
= 0.026) or deep myometrial invasion (
P
= 0.026). Multivariate Cox regression analysis revealed that lymph node metastasis was independently predictive of PFS, while advanced FIGO stage was an independent predictor of OS. No significant association between MMR status and prognosis was found in EC.
Conclusion
Higher SUVmax was associated with MMR deficiency in EC patients with endometrioid type, advanced stage, or deep myometrial invasion, which may be useful for predicting the MMR status and thus aiding in determination of immunotherapy for patients with EC.</description><subject>Cancer</subject><subject>Endometrial cancer</subject><subject>Endometrium</subject><subject>Fluorine isotopes</subject><subject>Imaging</subject><subject>Immunohistochemistry</subject><subject>Immunotherapy</subject><subject>Lymph nodes</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Mismatch repair</subject><subject>MMR protein</subject><subject>Myometrium</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Parameters</subject><subject>Positron emission tomography</subject><subject>Prognosis</subject><subject>Radiology</subject><subject>Regression analysis</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kb1uFDEURi0EEkvgBags0dCY-GfGY5fRkk0iRQrFUlt3bM-uo1l7sT2gPEVeGZONhJQi1b3FOZ_u1YfQZ0a_MUqH88I46zShXBDKlNSEv0GrtnREdkK8RSuqWUcGpob36EMp95Ry1Su-Qo8XpSQboIYUcZrwIZQDVLvH2R8hZOz8FGzw0T7gELGPLh18zQFmbCFan_GfUPeYqQ3ZfL_CPy635-sthuiwnUMMNh2h7tOcdsE2ZfJQl-zLE1D3vuUfc9rFVGqw-DfMi_-I3k0wF__peZ6hn5vL7fqa3N5d3awvbonlilfCnGVgtR-gl93ghPQgBu00pRoYSN6NbrTKCehUz4USYhyVUCNTVKi-l06coa-n3HbAr8WXatrn1s8zRJ-WYriSSkrVd6qhX16g92nJsV3XKE2VoEzrRvETZXMqJfvJHHM4QH4wjJp_HZlTR6Z1ZJ46MrxJ4iSVBsedz_-jX7H-ArDGlSU</recordid><startdate>20231201</startdate><enddate>20231201</enddate><creator>Sun, Xiaolin</creator><creator>Yao, Xinchao</creator><creator>Zeng, Baozhen</creator><creator>Zhu, Linbo</creator><creator>Shang, Yuxiang</creator><creator>Zhang, Qing</creator><creator>He, Li</creator><creator>Jiang, Lei</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9479-132X</orcidid></search><sort><creationdate>20231201</creationdate><title>Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value</title><author>Sun, Xiaolin ; Yao, Xinchao ; Zeng, Baozhen ; Zhu, Linbo ; Shang, Yuxiang ; Zhang, Qing ; He, Li ; Jiang, Lei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c282t-1dc1ac9e7a5647d36ea379d9009a1a624bdbc8d3a48523833bb838b18038556d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer</topic><topic>Endometrial cancer</topic><topic>Endometrium</topic><topic>Fluorine isotopes</topic><topic>Imaging</topic><topic>Immunohistochemistry</topic><topic>Immunotherapy</topic><topic>Lymph nodes</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Mismatch repair</topic><topic>MMR protein</topic><topic>Myometrium</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Parameters</topic><topic>Positron emission tomography</topic><topic>Prognosis</topic><topic>Radiology</topic><topic>Regression analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Xiaolin</creatorcontrib><creatorcontrib>Yao, Xinchao</creatorcontrib><creatorcontrib>Zeng, Baozhen</creatorcontrib><creatorcontrib>Zhu, Linbo</creatorcontrib><creatorcontrib>Shang, Yuxiang</creatorcontrib><creatorcontrib>Zhang, Qing</creatorcontrib><creatorcontrib>He, Li</creatorcontrib><creatorcontrib>Jiang, Lei</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Xiaolin</au><au>Yao, Xinchao</au><au>Zeng, Baozhen</au><au>Zhu, Linbo</au><au>Shang, Yuxiang</au><au>Zhang, Qing</au><au>He, Li</au><au>Jiang, Lei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><date>2023-12-01</date><risdate>2023</risdate><volume>37</volume><issue>12</issue><spage>655</spage><epage>664</epage><pages>655-664</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Purpose
Identification of the mismatch repair (MMR) deficiency in endometrial cancer (EC) may aid in the screening of patients who may benefit from immunotherapy. Our goal was to investigate the relationship between MMR status and
18
F-FDG PET/CT metabolic parameters and clinicopathological features in patients with EC, as well as to explore their prognostic value.
Methods
This retrospective study included 106 EC patients who were classified as MMR deficient (dMMR) or MMR proficient (pMMR) group based on MMR protein expression status evaluated by immunohistochemistry. Clinicopathological characteristics and PET metabolic parameters were compared between the dMMR and pMMR groups, and their relationships with MMR status and prognosis were evaluated.
Results
Of 106 EC patients, 30 patients (28.1%) had dMMR, while 76 (71.7%) had pMMR. Compared with the pMMR group, the dMMR group showed a lower prevalence of overweight (BMI ≥ 25) (17.2% vs. 43.9%,
P
= 0.019) and more lymph vascular space invasion (43.3% vs. 21.1%,
P
= 0.029). Although no relationship between glucometabolism parameters and MMR status was observed in all enrolled patients, higher SUVmax was observed in the endometrioid type of EC with MMR deficiency (
P
= 0.047). Additionally, SUVmax related to MMR status was found in EC patients with advanced FIGO stage (
P
= 0.026) or deep myometrial invasion (
P
= 0.026). Multivariate Cox regression analysis revealed that lymph node metastasis was independently predictive of PFS, while advanced FIGO stage was an independent predictor of OS. No significant association between MMR status and prognosis was found in EC.
Conclusion
Higher SUVmax was associated with MMR deficiency in EC patients with endometrioid type, advanced stage, or deep myometrial invasion, which may be useful for predicting the MMR status and thus aiding in determination of immunotherapy for patients with EC.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><doi>10.1007/s12149-023-01869-2</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-9479-132X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2023-12, Vol.37 (12), p.655-664 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2868668548 |
| source | SpringerLink Journals |
| subjects | Cancer Endometrial cancer Endometrium Fluorine isotopes Imaging Immunohistochemistry Immunotherapy Lymph nodes Medicine Medicine & Public Health Metabolism Metastases Mismatch repair MMR protein Myometrium Nuclear Medicine Original Article Parameters Positron emission tomography Prognosis Radiology Regression analysis |
| title | Association of mismatch repair deficiency in endometrial cancer with 18F-FDG PET/CT and clinicopathological features and their prognostic value |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T07%3A19%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20mismatch%20repair%20deficiency%20in%20endometrial%20cancer%20with%2018F-FDG%20PET/CT%20and%20clinicopathological%20features%20and%20their%20prognostic%20value&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Sun,%20Xiaolin&rft.date=2023-12-01&rft.volume=37&rft.issue=12&rft.spage=655&rft.epage=664&rft.pages=655-664&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-023-01869-2&rft_dat=%3Cproquest_cross%3E2890830199%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2890830199&rft_id=info:pmid/&rfr_iscdi=true |